Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNSDM1)

Drug Name

DMP-696 Drug Info

Synonyms

DMP 696; DMP-696; DMP696; CHEMBL44698; SCHEMBL2931046; GTPL3499; ZINC1489783; PDSP1_001296; PDSP2_001280; BDBM50084875; CS-6810; HY-12131; 8-(2,4-dichlorophenyl)-N-(1,3-dimethoxypropan-2-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine; [8-(2,4-Dichloro-phenyl)-2,7-dimethyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-(2-methoxy-1-methoxymethyl-ethyl)-amine; N-[1-(Methoxymethyl)-2-methoxyethyl]-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine-4-amine

Indication

Disease Entry	ICD 11	Status	REF
Anxiety disorder	6B00-6B0Z	Terminated	[1]

Cross-matching ID

PubChem CID: 9909468
CAS Number: CAS 202578-52-7
TTD Drug ID: DMNSDM1

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Corticotropin-releasing factor receptor 1 (CRHR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Telavancin	DM58VQX	Staphylococcus infection	1B5Y	Approved	[3]
Pexacerfont	DMBJ15R	Anxiety disorder	6B00-6B0Z	Phase 2/3	[4]
SSR125543	DMGJEB8	Anxiety disorder	6B00-6B0Z	Phase 2	[5]
ONO-2333Ms	DMOT0WR	Anxiety disorder	6B00-6B0Z	Phase 2	[6]
GSK561679	DMEVARK	Alcohol dependence	6C40.2	Phase 2	[7]
Tildacerfont	DMAB8LH	Congenital adrenal hyperplasia	5A71.01	Phase 2	[8]
GSK586529	DM5E9LX	Anxiety disorder	6B00-6B0Z	Phase 1	[7]
GW876008	DMAXRBI	Irritable bowel syndrome	DD91.0	Discontinued in Phase 2	[4]
CP-316,311	DMZ76EM	Major depressive disorder	6A70.3	Discontinued in Phase 2	[4]
CRA1000	DMWMBIV	Anxiety disorder	6B00-6B0Z	Preclinical	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Corticotropin-releasing factor receptor 1 (CRHR1)	TT7EFHR	CRFR1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3499).
2	In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists. J Med Chem. 2009 Jul 23;52(14):4161-72.
3	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
4	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
5	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
6	Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86.
7	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
8	Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021 Nov 30;186(1):R1-R14.